http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2015096856-A
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0377c5662bec0d4760f2b4b2f9101716 |
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-78 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6887 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12M3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 |
filingDate | 2014-11-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_21d96689970b8d1d3292ad23a0ccee1e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fc84d4a2e3a87454d2e69ccfd4b46a24 |
publicationDate | 2015-05-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | JP-2015096856-A |
titleOfInvention | Methods and compositions for diagnosing ankylosing spondylitis using biomarkers |
abstract | A method for determining the efficacy of a TNFα inhibitor, such as a TNFα antibody or antigen binding portion thereof, for the treatment of ankylosing spondylitis (AS). A predetermined level of a collagen degradation biomarker and / or synovitis biomarker obtained from an AS patient after treatment with a human TNFα antibody is expressed as a collagen degradation biomarker and / or synovitis biomarker related to a disease state. Comparing to a known standard level of the marker; and whether the patient's post-treatment collagen degradation biomarker and / or synovitis biomarker level is lower than the known standard level of the collagen degradation biomarker and / or synovitis biomarker Of the human TNFα antibody for the treatment of AS by having a collagen degradation biomarker and / or synovitis biomarker level obtained from a post-treatment patient lower than a known standard level Efficacy is shown. [Selection figure] None |
priorityDate | 2005-11-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 839.